Company:  AVEO PHARMACEUTICALS INC (AVEO)
Form Type:  10-K
Filing Date:  3/11/2013 
CIK:  0001325879 
Address:  650 E. KENDALL STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  (617) 299-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.37  
Change: 
0.01 (0.74%)  
Trade Time: 
Mar 27  
Market Cap: 
$71.43M

Description of Business
We are a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. Our proprietary platform has delivered unique insights into cancer and related disease. Our strategy is to leverage these biomarker insights and partner resources to advance the development of our clinical pipeline. As further described below, we currently are exploring partnership opportunities to fund the further development of three of our four development programs, including our lead program for tivozanib. Our development programs, which seek to advance our clinical stage assets, are as follows: * Tivozanib: In 2006, we acquired exclusive rights to develop and commercialize tivozanib, outside of Asia pursuant to a license agreement we entered into with Kirin Brewery Co. Ltd.
Register for a Free Trial and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. Business
      Legal Proceedings
      Item 1A. Risk Factors
      ITEM 1B. Unresolved Staff Comments
      ITEM 2. Properties
      ITEM 4. Mine Safety Disclosures
    PART II
      ITEM 5. Market for Registrant's Common Equity, Related ...
      ITEM 6. Selected Financial Data
      ITEM 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. Quantitative and Qualitative Disclosures About ...
      ITEM 8. Financial Statements and Supplementary Data
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Consolidated Financial Statements
      ITEM 9. Changes in and Disagreements with Accountants on ...
      ITEM 9A. Controls and Procedures
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
      ITEM 9B. Other Information
    PART III
      ITEM 10. Directors, Executive Officers and Corporate Governance
      ITEM 11. Executive Compensation
      ITEM 12. Security Ownership of Certain Beneficial Owners and ...
      ITEM 13. Certain Relationships and Related Person ...
      ITEM 14. Principal Accounting Fees and Services
    PART IV
      ITEM 15. Exhibits and Financial Statement Schedules
    Report of Independent Registered Public Accounting Firm
    SIGNATURES
    Exhibit Index
  EXHIBIT 10.18
  EXHIBIT 10.19
  EXHIBIT 21.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,